This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
A. P. Abernethy , G. Raman , E. M. Balk , J. M. Hammond , L. A. Orlando , J. L. Wheeler , J. Lau D. C. McCrory (2009), ‘Systematic review: reliability of compendia methods for off-label oncology indications’, Annals of Internal Medicine, 150: 336–343.
G. C. Alexander , L. P. Casalino D. O. Meltzer (2003), ‘Patient–physician communication about out-of-pocket costs’, Journal of the American Medical Association, 290(7): 953–958.
J. S. Ancker D. Kaufman (2007), ‘Rethinking health numeracy: a multidisciplinary literature review’, Journal of the American Medical Informatics Association, 14: 713–721.
P. B. Bach (2009), ‘Limits on Medicare's ability to control rising spending on cancer drugs’, New England Journal of Medicine, 360(6): 626–633.
A. E. Barnato , M. B. Herdon , D. L. Anthony , P. M. Gallagher , J. S. Skinner , J. P. W. Bynum E. S. Fisher (2007), ‘Are regional variations in end-of-life care intensity explained by patient preferences? A study of the US Medicare Population’, Medical Care, 45(5): 386–393.
K. Chalkidou (2012), ‘Evidence and values: paying for end of life drugs in the British NHS’, Health Economics, Policy and Law.
J. Cohen W. Looney (2010), ‘What is the value of oncology medicines?’, Nature Biotechnology, 28: 1160–1163.
P. M. Danzon E. Taylor (2010), ‘Drug pricing and value in oncology’, Oncologist, 15(Supplement 1): 24–31.
M. Drummond A. Towse (2012), ‘Is it time to consider the role of patient co-payments for pharmaceuticals in Europe?’, European Journal of Health Economics, 13(1): 1–5.
C. C. Earle , M. B. Landrum , J. M. Souza , B. A. Neville , J. C. Weeks J. Z. Ayanian (2008), ‘Aggressiveness of cancer near the end of life: is it a quality of care issue?’, Journal of Clinical Oncology, 26: 3860–3866.
R. R. Faden , K. Chalkidou , J. Appleby , H. R. Waters J. Leider (2009), ‘Expensive cancer drugs: a comparison between the United States and the United Kingdom’, Milbank Q, 87: 789–819.
T. Fojo C. Grady (2009), ‘How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question’, Journal of National Cancer Institute, 101: 1044–1048.
N. Freemantle M. F. Drummond (2010), ‘AHRQ Series Commentary 3: The United States addresses comparative effectiveness but not cost-effectiveness through the Effective Health-Care Program’, Journal of Clinical Epidemiology, 63: 479–480.
A. M. Garber H. C. Sox (2010), ‘The role of costs in comparative effectiveness research’, Health Affairs, 29(10): 1805–1811.
A. S. Gerber , E. M. Patashnik , D. Doherty C. Cowling (2010), ‘The public wants information, not broad mandates, from comparative effectiveness research’, Health Affairs, 29(10): 1872–1881.
D. P. Goldman , A. B. Jena , D. N. Lakdawalla , J. L. Malin , J. D. Malkin E. Sun (2010), ‘The value of specialty oncology drugs’, Health Services Research, 45(1): 115–132.
D. Goodman (2011), ‘End-of-life cancer care in Ontario and the United States: quality by accident or quality by design?’, Journal of the National Cancer Institute, 103(11): 1–2.
S. E. Harrington T. J. Smith (2008), ‘The role of chemotherapy at the end of life: “when is enough, enough”?’, Journal of the American Medical Association, 299: 2667–2678.
D. U. Himmelstein , D. Thorne , E. Warren S. Woolhandler (2009), ‘Medical bankruptcy in the United States, 2007: results of a national study’, American Journal of Medicine, 122: 741–746.
J. Hsu , M. Price , J. Huang , R. Brand V. Fung (2006), ‘Unintended consequences of caps on Medicare drug benefits’, New England Journal of Medicine, 354: 2349–2359.
M. Jacobson , A. J. O'Malley , C. C. Earle , J. Pakes , P. Gaccione J. P. Newhouse (2006), ‘Does reimbursement influence chemotherapy treatment for cancer patients?’, Health Affairs, 25: 437–443.
P. Kim (2007), ‘Costs of cancer: the patient perspective’, Journal of Clinical Oncology, 25(2): 228–232.
K. M. Langa , A. M. Fedrick , M. E. Chernew , M. U. Kabeto , K. L. Paisley J. A. Haymen (2004), ‘Out-of-pocket health care expenditures among older Americans with cancer’, Value Health, 7(2): 186–194.
J. D. Lubitz G. F. Riley (1993), ‘Trends in Medicare payments in the last year of life’, New England Journal of Medicine, 328(15): 1092–1096.
J. L. Malin (2010), ‘Wrestling with the high price of cancer care: should we control costs by individuals’ ability to pay or society's willing to pay?’, Journal of Clinical Oncology, 28(20): 3212–3214.
C. McNeil (2007), ‘Sticker shock sharpens focus on biologics’, Journal of National Cancer Institute, 99(12): 910–914.
N. J. Meropol , D. Schrag , T. J. Smith , T. M. Mulvey , R. M. Langdon , D. Blum , P. A. Ubel L. E. Schnipper (2009), ‘American Society of Clinical Oncology guidance statement: the cost of cancer care’, Journal of Clinical Oncology, 27(23): 3868–3874.
N. J. Meropol K. A. Schulman (2009), ‘Cost of cancer care: issues and implications’, Journal of Clinical Oncology, 25(2): 180–186.
C. D. Mullins , R. Montgomery S. Tunis (2010), ‘Uncertainty in assessing value of oncology treatments’, Oncologist, 15(Supplement 1): 58–64.
E. Nadler , B. Eckert P. J. Neumann (2006), ‘Do oncologists believe new cancer drugs offer good value?’, Oncologist, 11(2): 90–95.
P. J. Neumann , J. A. Palmer , E. Nadler , C. Fang P. Ubel (2010), ‘Cancer therapy costs influence treatment: a national survey of oncologists’, Health Affairs, 29(1): 196–202.
P. J. Neumann , E. A. Sandberg , C. M. Bell , P. W. Stone R. H. Chapman (2000), ‘Are pharmaceuticals cost-effective? A review of the evidence’, Health Affairs, 19(2): 92–109.
S. D. Pearson P. B. Bach (2010), ‘How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement’, Health Affairs, 29(10): 1796–1804.
S. Ramsey A. Schickedanz (2010), ‘How should we define value in cancer care?’, The Oncologist, 15(Supplement 1): 1–4.
M. D. Rawlins K. Chalkidou (2011), ‘The opportunity cost of cancer care: a statement from NICE’, Lancet Oncology, 12(10): 931–932.
L. E. Schnipper , N. J. Meropol D. W. Brock (2010), ‘Value and cancer care: toward an equitable future’, Clinical Cancer Research, 16(24): 6004–6008.
S. Schrag M. Hanger (2007), ‘Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey’, Journal of Clinical Oncology, 25: 233–237.
S. Schrag (2004), ‘The price tag on progress – chemotherapy for colorectal cancer’, New England Journal of Medicine, 351(4): 317–319.
A. Schickedanz (2010), ‘Of value: a discussion of cost, communication, and evidence to improve cancer care’, Oncologist, 15(Supplement 1): 73–79.
T. J. Smith B. E. Hillner (2011), ‘Bending the cost curve in cancer care’, New England Journal of Medicine, 364(21): 2060–2065.
T. J. Smith B. E. Hillner (2010), ‘Concrete options and ideas for increasing value in oncology care: the view from one trench’, Oncologist, 15(Supplement 1): 65–72.
M. L. Slevin , L. Stubbs , J. J. Plant , P. Wilson , W. M. Gregory , P. J. Armes S. M. Downer (1990), ‘Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public’, British Medical Journal, 300: 1458–1460.
H. Sox (2009), ‘Evaluating off-label uses of anticancer drugs: time for a change’, Annals of Internal Medicine, 150(5): 353–354.
D. P. Sulmasy (2007), ‘Cancer care, money, and the value of life: whose justice? Which rationality?’, Journal of Clinical Oncology, 25(2): 217–222.
K. S. Virgo , A. M. Vernava , W. E. Longo , M. E. Kissling , J. C. Lin F. E. Johnson (1995), ‘Cost of patient follow-up after potentially curative colorectal cancer treatment’, Journal of the American Medical Association, 273: 1837–1841.
U. Wong , O. Hamilton , B. Egleston , K. Salador , C. Murphy N. J. Meropol (2010), ‘Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices’, The Oncologist, 15: 566–576.
A. A. Wright , B. Zhang , A. Ray , J. W. Mack , E. Trice , T. Balboni , S. L. Mitchell , V. A. Jackson , S. D. Block , P. K. Maciejewski H. G. Prigerson (2008), ‘Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment’, Journal of the American Medical Association, 300: 1665–1673.
B. Zhang , A. A. Wright , H. A. Huskamp , M. E. Nilsson , M. L. Maciejewski , C. C. Earle , S. D. Block , P. K. Maciejewski H. G. Prigerson (2009), ‘Health care costs in the last week of life: associations with end-of-life conversations’, Archives of Internal Medicine, 169: 480–488.
F. K. Tangka , J. G. Trogdon , L. C. Richardson , D. Howard , S. A. Sabatino E. A. Finkelstein (2010), ‘Cancer treatment cost in the United States. Has the burden shifted over time?’, Cancer, 116(14): 3477–3484.